|Day Low/High||0.81 / 0.85|
|52 Wk Low/High||0.80 / 3.09|
H.C. Wainwright reduced Galectin Thereapeutics' (GALT) stock rating to 'neutral' after the company's fatty liver disease drug failed in a phase II clinical trial.
Galectin Therapeutics' (GALT) stock rating was cut two notches to 'sell' at Roth Capital on Wednesday after the company's drug for fatty liver disease failed a clinical trial.
These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.
Meaningful activity of GR-MD-02 in treating psoriasis suggests promise in treatment of non-alcoholic steatohepatitis (NASH), the company's primary target
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that Peter G.
Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received a Notice of Allowance from the...
Researchers at Augusta University show galectin-3 inhibitors improve PAH in animal models
Top line results of the NASH-FX trial to be reported in September 2016
Conference Call to Begin at 8:30 a.m. ET Today
United States District Court Dismisses Both Actions With Prejudice